Clearmind Medicine and Yissum File International Patent for Gen 3.0 Psychedelics to Treat Mental Disorders

Clearmind Medicine Inc., a biotechnology firm headquartered in Vancouver, Canada, has recently filed a patent application under the international Patent Cooperation Treaty (PCT). This filing is a significant step in their collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem. The company, listed on Nasdaq under CMND and on the Frankfurt Stock Exchange under CWY0, focuses on developing new psychedelic-derived therapeutics to address health issues that are currently under-treated.

The patent application centers on the third generation of psychedelic compounds, including their preparation methods and their potential uses in treating mental disorders. These compounds were developed by Professor Dmitry Tsvelikhovsky of the Hebrew University of Jerusalem. The PCT submission will enable Clearmind to move forward with applications in multiple regions, seeking patent protection in major markets such as the United States, Europe, China, and India.

Dr. Adi Zuloff-Shani, the CEO of Clearmind, emphasized the importance of this patent submission. According to Dr. Zuloff-Shani, the approval of this patent would secure crucial intellectual property rights for the company. She expressed confidence in the potential of psychedelic treatments as effective tools for addressing mental health disorders. Dr. Zuloff-Shani also highlighted Clearmind's role as a leader in the field of psychedelic therapeutics, committed to advancing innovation. She noted that the new generation of psychedelic compounds, featuring advanced molecules, might significantly improve the quality of life for patients suffering from mental disorders.

Yissum, the technology transfer arm of the Hebrew University of Jerusalem, is a key player in this initiative. Established in 1964, Yissum aims to bridge the gap between academic research and the commercial sector. It has a long history of converting innovative technologies into practical solutions that address global challenges. To date, Yissum has registered over 11,680 patents worldwide, licensed more than 1,160 technologies, and spun out over 260 companies. The organization collaborates with a broad network of global partners, including entrepreneurs, investors, and industrial entities.

Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company. Its primary mission is to discover and develop novel psychedelic-derived compounds to address widespread and under-served health issues, such as alcohol use disorder. The company's intellectual property portfolio consists of nineteen patent families, and it aims to expand this portfolio as new opportunities arise. Clearmind is committed to researching, developing, and commercializing psychedelic-based treatments, which they plan to offer as regulated medicines, foods, or supplements.

Clearmind's collaboration with Yissum signifies a strategic move to leverage cutting-edge academic research for commercial applications. This partnership aims to generate innovative solutions that can meet urgent global health challenges. The recent PCT submission is a testament to Clearmind's commitment to pioneering advancements in psychedelic therapeutics. By securing patent protection in major jurisdictions, Clearmind intends to solidify its position as a leading entity in the field and bring forth new treatment options for mental health disorders.